Biorce brings Aika 2.0 to BIO 2026 with live demo rides in San Diego

Oncology protocols amend more often and differently, with higher amendment rates, greater complexity, and sharper consequences for trial completion.

Protocol amendments cost hundreds of thousands of dollars and add months to trials. Discover the hidden financial and operational impact of protocol changes.

Aika's AI-generated protocol anticipated 54.8% of eligibility criteria later added through protocol amendments. Reduce clinical trial delays and costs.

Every week I talk to clinical development leaders trying to move faster with AI.

LinkedIn influencer Joanna Sadowska explores how AI is transforming drug discovery and development, empowering scientists and patients with better tools.

Biorce CEO Pedro Coelho talks with Paolo Martini about resilience, purpose, and the mission to ensure science and innovation improve patient lives.

Every data point is a person waiting for a better outcome. Here's why we made a film about hope before talking about technology.

Biorce stood out at ASCO 2026, taking the Aika 2.0 product launch into the city. Forget the Booth. This demo came with a seatbelt.

The FDA's RTCT initiative is bringing regulators closer to live trial data. The real question is whether trial infrastructure can keep pace.

Biorce is launching Aika 2.0 at ASCO 2026 with a ride experience, introducing the end-to-end operating system for clinical trials.

XTalks webinar with Pedro Coelho (Biorce CEO), Paolo Martini (Two Hundred Thousand Consulting LLC), and Bruno Gagnon (Spruce)

Adam Taylor (GSK) and Biorce CEO Pedro Coelho discuss trial inefficiencies, personalized medicine, and the role of defensible AI.

Biorce makes its mark with a bold conference as the life sciences industry gathers in Boston for a landmark week of events.

Pierre-Antoine André (IQVIA), with 25+ years across pharma, joins CEO Pedro Coelho to unpack where AI is truly creating impact.